David Budd

David is SVP, Head of Drug Discovery at Quotient Therapeutics. He brings nearly three decades of experience spanning academic research, drug discovery and early clinical development, beginning with postdoctoral research at the University of Leicester and progressing through roles at Novartis and Roche.

At GSK, David led early- and mid-stage programs in pulmonary vascular disease, autoimmune conditions and rare diseases. Most recently, he led Relation’s osteoporosis portfolio and osteoarthritis collaboration, applying AI/ML, multi-omics and experimental biology to identify new therapeutic targets.

David received his BSc in biochemistry from the University of Glasgow and his PhD in biochemistry from the University of Dundee.